Our portfolio company, Novadiscovery announced an expanded partnership with Janssen.
The partnership initially entered in 2020. At the time, Janssen selected Novadiscovery to help provide answer to key clinical development questions in the future of healthcare.
Novadiscovery is now implementing its JINKO clinical trial simulation platform for the development of lung cancer models.
Janssen intends to use computational disease models to investigate benefits of in silico trials on Non-Small cell lung cancer (NSCLC).